Results 81 to 90 of about 5,421 (159)

Case report: Successful treatment of OXA-23 neurosurgical infection and meningitis with sulbactam-durlobactam combination therapy

Meningitis caused by species is a rare complication of neurosurgical procedures, although it is associated with high morbidity and mortality. Carbapenem-resistant is particularly difficult to treat, considering the limited selection and tolerability of
Rawlings, Stephen A, Snowdin, Jacob W, Madaio, Michael P, Mercuro, Nicholas J   +3 more
core   +1 more source

In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations

Microbiology Spectrum
Carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. represent major threats and have few approved therapeutic options. Non-‍fermenting Gram-negative isolates were collected from hospitalized inpatients from 49 sites in 6 European countries
Anne Santerre Henriksen, Katy Jeannot, Antonio Oliver, John D. Perry, Mathias W. Pletz, Stefania Stefani, Ian Morrissey, Christopher Longshaw   +7 more
doaj   +1 more source

Sulbactam-containing β-lactamase inhibitor combinations [PDF]

, 2008
Sulbactam irreversibly inhibits the hydrolytic activity of β-lactamases. This compound is commercially available in combination with either ampicillin or cefoperazone. In each instance, the activity of the partner antibiotic against β-lactamase-producing
Sierra Valverde, Álvaro Javier, Akova, M.   +1 more
core   +1 more source

Resistance to sulbactam/durlobactam in carbapenem-resistant Acinetobacter baumannii in treatment-naive setting: in vitro data and genomic insights from Italian bloodstream isolates

Objectives: This study evaluated the in vitro activity of sulbactam/durlobactam and comparators against carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream isolates from Italy and investigated genomic mechanisms underlying resistance. Methods:
Boattini, Matteo, Biffignandi, Gherard Batisti, Vumbaca, Michela, Comini, Sara, Costa, Cristina, Gaibani, Paolo, Bianco, Gabriele   +6 more
core   +1 more source

Treatment Strategies of Colistin Resistance Acinetobacter baumannii Infections

Antibiotics
Acinetobacter baumannii has emerged as a pressing challenge in clinical practice, mainly due to the development of resistance to multiple antibiotics, including colistin, one of the last-resort treatments.
Andria Papazachariou, Renatos-Nikolaos Tziolos, Stamatis Karakonstantis, Petros Ioannou, George Samonis, Diamantis P. Kofteridis   +5 more
doaj   +1 more source

Avaliação da suscetibilidade a sulbactam-durlobactam e sua combinação com meropenem em isolados do complexo Acinetobacter baumannii provenientes de hemoculturas [PDF]

Introdução: Acinetobacter baumannii (AB) é um importante patógeno nosocomial associado a resistência a múltiplos antibióticos, particularmente carbapenêmicos.
Galvão, Mileny Rosalina
core  

Self‐Assembling Hydrogel‐Based Controlled Delivery of Sulbactam–Durlobactam and Cefiderocol Against Carbapenem‐Resistant Acinetobacter baumannii

Carbapenem‐resistant Acinetobacter baumannii (CRAB) has emerged as a major global healthcare threat because of its multidrug resistance, biofilm‐forming ability, and ...
R. Sowmya, Krithika Shree Sivasuriyan, S. Karthick Raja Namasivayam, Amrish Varshan G.S   +3 more
core   +1 more source

Μελέτη νεότερου αναστολέα β-λακταμασών σε ανθεκτικά στις καρβαπενέμες στελέχη Acinetobacter baumannii

, 2022
ΕΙΣΑΓΩΓΗ: Το Acinetobacter baumannii αποτελεί κύρια αιτία λοιμώξεων σχετιζόμενων με χώρους υγειονομικής περίθαλψης, εξαιτίας της επιμονής του ως αποικιστή στο νοσοκομειακό περιβάλλον και της ικανότητας του να αποκτά υψηλού επιπέδου αντοχή.
Petropoulou Dimitra, Πετροπούλου Δήμητρα   +1 more
core   +1 more source

Re: Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates : author's response

Authors' reply to : Veeraraghavan B, Walia K, Egli A. Re: 'Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates' by Poirel et al.
Le Terrier, Christophe, Nordmann, Patrice, Poirel, Laurent   +2 more
core   +1 more source

Successful Treatment with Sulbactam-Durlobactam for Severe Acute Pancreatitis Complicated by Extensively Drug-Resistant Acinetobacter baumannii Infection at Multiple Sites: A Case Report

Infection and Drug Resistance
Zhengmao Ge, Li Li, Longxin Wang, Dengke Liu, Yupeng Liu Department of Critical Care Medicine, The 967 Hospital, Joint Logistics Support Force of PLA, Dalian, 116021, People’s Republic of ChinaCorrespondence: Yupeng Liu, Department of Critical Care ...
Ge Z, Li L, Wang L, Liu D, Liu Y
doaj